CytoDyn Inc. (CYDY): Price and Financial Metrics
CYDY Price/Volume Stats
| Current price | $0.12 | 52-week high | $0.32 |
| Prev. close | $0.12 | 52-week low | $0.10 |
| Day low | $0.12 | Volume | 4,229,000 |
| Day high | $0.13 | Avg. volume | 2,552,000 |
| 50-day MA | $0.13 | Dividend yield | N/A |
| 200-day MA | $0.15 | Market Cap | 145.10M |
CYDY Stock Price Chart Interactive Chart >
CytoDyn Inc. (CYDY) Company Bio
CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
CYDY Price Returns
| 1-mo | 1.61% |
| 3-mo | -24.95% |
| 6-mo | -14.16% |
| 1-year | -39.73% |
| 3-year | -88.68% |
| 5-year | -80.33% |
| YTD | -38.46% |
| 2023 | -13.33% |
| 2022 | -77.24% |
| 2021 | -81.66% |
| 2020 | 439.00% |
| 2019 | 112.77% |
Loading social stream, please wait...